

1 **Manuscript Title**

2 Ultrasound Shear Wave Attenuation Imaging for Grading Liver Steatosis in Volunteers and
3 Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study

4

5 **Authors:**

6 Ladan Yazdani, MSc ^{1,2}

7 Iman Rafati, MSc ^{1,2}

8 Marc Gesnik, PhD ¹

9 Frank Nicolet, MSc ¹

10 Boris Chayer, M. Eng. ¹

11 Guillaume Gilbert, PhD ^{3,4}

12 Anton Volniansky, ⁴

13 Damien Olivié, MD ⁴

14 Jeanne-Marie Giard, MD, MPH ⁵

15 Giada Sebastiani, MD ⁶

16 Bich N. Nguyen, MD⁷

17 An Tang, MD, MSc ^{4,8}

18 Guy Cloutier, PhD, Eng. ^{1,2,4}

19

20 **Affiliations:**

21 ¹ Laboratory of Biorheology and Medical Ultrasonics (LBUM), Centre de recherche du
22 Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada;

23 ² Institute of Biomedical Engineering, Université de Montréal, Montréal, Québec, Canada;

24 ³ MR Clinical Science, Philips Healthcare Canada, Markham, Ontario, Canada;

25 ⁴ Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de
26 Montréal, Montréal, Québec, Canada;

27 ⁵ Department of Hepatology, Université de Montréal, Montréal, Québec, Canada;

28 ⁶ Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal,
29 Quebec, Canada;

30 ⁷ Service of Pathology, Centre hospitalier de l'Université de Montréal (CHUM), Montréal,
31 Québec, Canada;

32 ⁸ Laboratory of Clinical Image Processing, CRCHUM, Montréal, Québec, Canada.

33

34 **Author Information:**

35 **Ladan Yazdani:** Laboratory of Biorheology and Medical Ultrasonics, University of Montreal
36 Hospital Research Center, 900 Saint-Denis, room R11-720, Montreal, Quebec, Canada, H2X
37 0A9, phone: 514-890-8000 #31423, fax: N/A, email: ladan.yazdani@umontreal.ca.

38

39 **Iman Rafati:** Laboratory of Biorheology and Medical Ultrasonics, University of Montreal
40 Hospital Research Center, 900 Saint-Denis, room R11-720, Montreal, Quebec, Canada, H2X
41 0A9, phone: 514-890-8000 #31423, fax: N/A, email: iman.rafati@umontreal.ca

42

43 **Marc Gesnik:** Laboratory of Biorheology and Medical Ultrasonics, University of Montreal
44 Hospital Research Center, 900 Saint-Denis, room R11-720, Montreal, Quebec, Canada, H2X
45 0A9, phone: 514-890-8000 #31423, fax: N/A, email: marc.gesnik@iconeus.com ; now at
46 Iconeus, Paris 75014, France.

47

48 **Frank Nicolet:** Laboratory of Biorheology and Medical Ultrasonics, University of Montreal
49 Hospital Research Center, 900 Saint-Denis, room R11-720, Montreal, Quebec, Canada, H2X
50 0A9, phone: 514-890-8000 #31423, fax: N/A, email: frank.nicolet@creatis.insa-lyon.fr; now at
51 CREATIS, University of Lyon, France.

52

53 **Boris Chayer:** Laboratory of Biorheology and Medical Ultrasonics, University of Montreal
54 Hospital Research Center, 900 Saint-Denis, room R11-720, Montreal, Quebec, Canada, H2X
55 0A9, phone: 514-890-8000-30309, fax: N/A, email: boris.chayer.chum@ssss.gouv.qc.ca

56

57 **Guillaume Gilbert:** MR Clinical Science, Philips Healthcare Canada, 1875 Buckhorn Gate, 5th
58 floor, Mississauga, Ontario, Canada, L4W 5P1, phone: 438-998-4138, fax: N/A, email:
59 guillaume.gilbert@philips.com

60

61 **Anton Volniansky:** Department of Radiology, Centre hospitalier de l'Université de Montréal
62 (CHUM), 1000, rue Saint-Denis, Montreal, Québec, Canada, H2X 0C1, phone: N/A, fax: N/A,
63 email: anton.volniansky.med@ssss.gouv.qc.ca

64

65 **Damien Olivie:** Department of Radiology, Centre hospitalier de l'Université de Montréal
66 (CHUM), 1000, rue Saint-Denis, Montreal, Québec, Canada, H2X 0C1, phone: 514-890-8450,
67 fax: N/A, email: damien.olivie@umontreal.ca

68

69 **Jeanne-Marie Giard:** Department of Hepatology, Université de Montréal, Montréal, Québec,
70 Canada, H3T 1J4, 514/890-8000, fax: N/A, email: jeannemariegiard@gmail.com

71

72 **Giada Sebastiani:** Division of Gastroenterology and Hepatology, McGill University Health
73 Centre, Montreal, Quebec, Canada, H2X 0C1, phone: 514-843-1616 , fax: N/A, email:
74 giada.sebastiani@mcgill.ca

75

76 **Bich N. Nguyen:** Service of pathology, CHUM, 1051, rue Sanguinet, Montréal (Québec) H2X
77 0C1, phone: 514-890-8000 #21208, fax: N/A, email: bich.ngoc.nguyen.med@ssss.gouv.qc.ca

78

79 **An Tang:** Laboratory of Clinical Image Processing, CRCHUM, 900 Saint-Denis, Montreal,
80 Quebec, Canada, H2X 0A9, phone: 514-890-8000 #11915, fax: N/A, email:
81 an.tang@umontreal.ca

82

83 **Guy Cloutier** (Corresponding Author): Laboratory of Biorheology and Medical Ultrasonics,
84 University of Montreal Hospital Research Center, 900 Saint-Denis, room R11-464, Montreal,
85 Quebec, Canada, H2X 0A9, phone: 514-890-8000 #24703, fax: N/A, email:
86 guy.cloutier@umontreal.ca, web: www.lbum-crchum.com

87

88 **Funding information:**

89 This work was supported in part by the Natural Sciences and Engineering Research Council of
90 Canada under Grant 2022-03729, in part by the Canadian Institutes of Health Research under
91 Grant 389385, and in part by the Oncotech consortium (Oncopole, Medteq, Transmedtech,
92 Cancer Research Society, Fonds de Recherche Santé du Québec, and Siemens Healthcare)
93 under Grant 293741. Salary award by the Fonds de recherche du Québec en Santé and
94 Fondation de l'association des radiologistes du Québec (FRQS-FARQ #298509) was obtained
95 by An Tang. Giada Sebastiani is supported by a Senior Salary Award from FRQS (#296306).

ELECTRONIC SUPPLEMENT

S1. Safety Usage of the Research Ultrasound Scanner in Shear Wave Elastography

Mode

I. Introduction

The human liver imaging sequence developed for this study successively performed ultrasound transmissions and receptions ¹. **Fig. S1** shows the ultrasound sequence that included B-mode imaging, quantitative ultrasound imaging (QUS, not used in the current study), and 10 shear wave elastography (SWE) acquisitions.

First, conventional B-mode imaging was used to position the plane and the push location for SWE image acquisitions. The QUS mode allowed acquiring 30 radiofrequency (RF) images. Each image was obtained by compounding divergent wave images at 21 different angles (from -10° to 10°) at a frame rate of 150 per second.

Then, in the SWE mode, each acquisition included 10 SW propagation at the same depth but with different acoustic radiation force angles (-5° to 5°). The advantages of using 10 acquisitions with small angle differences are as follows:

1) Automatization of the 10 acquisitions: The technologist only had to set one push location (the 0° push), far away from blood vessels; then, the 10 acquisitions were made automatically by pushing near this location at small angles (ranging from -5° to 5° in polar coordinates), ensuring that they were far from blood vessels too. This simplified the acquisition process for users by reducing it to the click of a button.

2) Temporal consistency: Since there was no need to manually select 10 push zones in succession, the time between acquisitions and the process of saving each acquisition were reduced and performed automatically.

120 3) Security aspect: The pushes from successive acquisitions were generated in different
121 directions, thereby limiting the amount of heating. This ensured additional safety during the
122 procedure.

123 In summary, this approach simplified the acquisition process for technologists while
124 maintaining consistency between acquisitions. Each push was made in a zone defined by the
125 sonographer supervised by a clinical radiologist, ensuring that all pushes targeted the liver
126 parenchyma and avoided major vessels.

127 Each SWE acquisition begun by focusing 5 pushes (992 cycles long, 357 μ s long) at a
128 given angle and 5 axially adjacent points with 3 mm distances in depth to produce a plane SW
129 ². The focused push beams were transmitted by 64 elements of the transducer at a center
130 frequency of 2.8 MHz. A radiology technologist positioned the first and last push locations to
131 ensure that all of them targeted liver parenchyma and avoided major vessels. The same
132 transducer was used to track SWs immediately after their propagation at a pulse repetition
133 frequency (PRF) of 6,225 Hz. The propagation of SWs was then tracked by acquiring 100
134 frames made of ultrafast (2,083 frames per second) divergent waves. At the end of the
135 sequence, the scanner was frozen. Parameters used in this sequence are presented in **Table**
136 **S1**.

137 Measurements were made to make sure that the energy and acoustic pressure of B-
138 mode, and SWE-mode met regulation standards. The chosen method was inspired by the work
139 of Herman and Harris ³ and Palmeri *et al.* ⁴. Shortly, the maximum of the peak rarefaction was
140 measured using a hydrophone to determine the mechanical index (MI), and the intensity spatial
141 peak temporal averaged (I_{SPTA}). The thermal index was computed from those maxima. MI
142 indicates the ultrasound sequence's ability to cause cavitation-related bioeffects. I_{SPTA}
143 corresponds to the maximum beam intensity averaged over the examination duration. The

144 thermal index corresponds to the quantification of the rise in tissue temperature that may occur
145 during the examination ^{3, 4}. The food and drug administration (FDA) of the United States
146 recommends to keep either the MI below 1.9 or the intensity spatial peak pulse averaged (ISPPA)
147 below 190 W/cm² ^{5, 6}. The limiting values for MI and ISPPA are not independent; if either one of
148 them falls below the designated FDA limit, then the other is permitted to exceed the limit ⁷. The
149 limit for the ISPTA is 720 mW/cm² as elastography complies with track 3 in ^{5, 6, 8}, while the thermal
150 index must remain under 6 °C ^{4, 5}. In this work, MI, ISPTA, and thermal index were assessed to
151 investigate the compliance with FDA limits. The maximal sonication power was then limited for
152 the safety of volunteers and patients, and approved by the institutional review board of the
153 Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM).

154

155 **II. Acoustic Measurements**

156 MI, ISPTA, and the thermal index were determined for the selected imaging sequence. A
157 membrane hydrophone (HMB-0200, ONDA Corp., Sunnyvale, CA, USA) connected to a digital
158 oscilloscope (CompuScope 12501, Vitrek LLC, Lockport, IL, USA) was positioned at the bottom
159 of a double-distilled deionized water tank. The research ultrasound system (Verasonics
160 Vantage, Kirkland, WA, USA) was connected to the ATL C5-2 clinical probe (Philips Healthcare,
161 Andover, MA, USA). The 100 MHz hydrophone sampled signals were converted to sound
162 pressure (Pascal) using the sensitivity of the hydrophone at 2.8 MHz (196 mV/Pa). The
163 ultrasound probe was attached to a computer-controlled multi-axis robotic system (ACR9000,
164 Parker Hannifin Corp., Rohnert Park, CA, USA) to localize the maximum pressure position.
165 Because acoustic power measurements were made in a water tank and not in an attenuating
166 tissue environment, the FDA recommends to compensate the attenuation by using a derating

167 attenuation factor of $\alpha = 0.3 \text{ dB.MHz}^{-1}.\text{cm}^{-1}$. The perpendicularity between the hydrophone and
168 the probe was aligned manually using the real-time focused B-mode.

169 A dedicated pressure measurement strategy was programmed using Matlab
170 (Mathworks, Natick, MA, USA) to synchronise Verasonics sequence transmissions during
171 hydrophone measurements. Transmitted voltages of 10, 20, 30, 40, and 50 V were studied for
172 a focus distance between the probe and the location of the push of 20, 30, 40, 60, and 80 mm.
173 SWE acoustic pressure measurements included 50 cycles pushes instead of 992 cycles to
174 prevent hydrophone damage (as the amplitude of pushes is constant, this did not impact the
175 identification of the peak rarefaction maximum). Every ultrasound emission was repeated 16
176 times for averaging purpose. Because acoustic outputs in SWE-mode are much higher than in
177 B-mode or QUS-mode, results given next correspond to the SWE sequence component.

178

179 **III. Results**

180 **1. Mechanical Index (MI)**

181 MI as a function of focus depths and selected voltages for a derating value of 0.3
182 $\text{dB.MHz}^{-1}.\text{cm}^{-1}$ is presented in **Fig. S2**. To stay below the FDA limit of 1.9, the maximum voltage
183 for SWE measurements at depths ≥ 40 mm was limited to 42 V. For smaller depths, the voltage
184 was limited to 25 V (**Table S2**). For comparison, MI in B-mode with parameters of **Table S1**
185 was 0.28.

186

187 **2. Intensity Spatial Peak Temporal Averaged (I_{SPTA})**

188 I_{SPTA} results as a function of depth are given in **Fig. S3** for selected voltages in **Table S2**.
189 For every acoustic radiation force depth, I_{SPTA} was lower than the FDA threshold of 720

190 mW/cm². This was achieved by adjusting the delay between the 10 SWE repetitions. In B-
191 mode, it was 6.15 mW/cm².

192

193 **3. Thermal Index**

194 **Fig. S4** presents the estimated thermal index in soft tissues of the SWE sequence as a
195 function of depth for voltages in **Table S2**. For every push focus depth, the index was close to
196 4 °C and below the FDA threshold of 6 °C. The estimated thermal index in B-mode using the
197 parameters of **Table S1** was 0.09 °C.

198 **IV. Discussion**

199 The result in **Fig. S2** showed that the research ultrasound system could exceed FDA
200 safety criteria when the selected voltage was not constrained within a safe range for given
201 acoustic radiation force depths. SWE pushes are particularly at risk of overrunning FDA limits
202 since they combine the use of focused waves, high voltages, and several hundreds of emitted
203 cycles.

204 According to the FDA, compliance with the restriction of MI and I_{SPTA} is sufficient to limit
205 the risk from acoustic output exposure levels ^{5, 6}. These two parameters are below the FDA
206 limits based on the results in **Fig. S2** and **Fig. S3**. As also reported, the thermal index is not
207 well suited for the acoustic radiation force imaging (ARFI) and SWE imaging modalities ^{9, 10}.
208 According to ¹¹, for the thermal index of 4, the maximum safe duration of examination without
209 thermal risk would be 15 seconds, while all liver imaging sequence in this work lasted less than
210 10 seconds. Furthermore, as each SWE repetition uses a different radiation angle, diffusion
211 can occur and reduce the heating inside the liver ¹². Thermal index values were presented here
212 for informative purpose only. Throughout our sequence design process, safety margins have

213 been added to the various parameters of the sequence to respect the principle of ALARA (as
214 low as reasonably achievable). By fixing the maximum voltage at a given depth, the sequence
215 used for this NAFLD human study met all safety criteria recommended by the FDA. By applying
216 the ALARA principle, it was decided to lengthen delays between SWE acoustic radiation force
217 pushes to reduce the frame rate, and to change the angle between the 10 consecutive push
218 lines to increase the safety for human liver scanning. In addition, it took about one minute to
219 save RF data after running the sequence. During data saving, no ultrasonic emissions were
220 possible, further reducing the risk of thermal overheating.

221

222 **S2. Ultrasound Shear Wave Data Acquisition and Parameter Computation**

223

224 **I. Shear Wave Attenuation (SWA)**

225 The revisited frequency shift (R-FS) method was used for SWA computation¹³. This
226 algorithm assumes the amplitude spectrum of SWs to be proportional to a gamma density
227 distribution. If a SW has a frequency spectrum $S(f)$ at a lateral distance x_0 , then:

$$228 \quad |S(f)| \propto f^{k_0-1} e^{-f/\beta_0}$$

229 where f is the SW frequency, and k_0 and β_0 are the shape and rate parameters of the gamma
230 function, respectively. The attenuation coefficient (α) was computed by fitting the gamma
231 spectrum at a lateral distance Δx , and finding the slope of the rate parameter with respect to
232 Δx (i.e., $\beta(\Delta x) = \beta_0 + \alpha \Delta x$)¹³. Both the shape and rate parameters are allowed to vary with the R-
233 FS method, and the adaptive random sample consensus (A-RANSAC) algorithm was used for
234 line fitting¹³. Two examples of line fitting of the rate parameter for SWA computation are shown
235 in **Fig. S5** (panels a and b).

236 Ten SWA maps were reconstructed from each acquisition by applying the R-FS method on
237 the defined ROI. SWA coefficients were averaged on each pixel using images with gamma
238 fitting providing coefficients of determination $R^2 > 0.8$ or larger. The averaging procedure for
239 obtaining the final attenuation map is shown in **Fig. S6**.

240

241 II. Shear Wave Dispersion (SWD)

242 SWD was estimated as the slope of the SW phase velocity versus frequency, according to
243 ^{14, 15}, on the same ROI as SWA computations by averaging the velocity field over depth. The
244 A-RANSAC method was used for line fitting and for finding the slope. Two examples of line
245 fitting of SW phase velocity are shown in **Fig. S5** (panels c and d). The SWD was computed
246 between averaged values of the lower frequency at half maximum (67 Hz) and peak frequency
247 (110 Hz), determined *a posteriori* on the whole dataset. For a given acquisition, SWD values
248 were estimated from ten SW records, and the mean and standard deviation (SD) were
249 computed for line fittings with $R^2 > 0.8$ or larger.

250 Electronic Supplement References

- 251 1. Deng Y, Rouze NC, Palmeri ML, Nightingale KR. Ultrasonic shear wave elasticity
252 imaging sequencing and data processing using a Verasonics research scanner. IEEE
253 Trans. Ultrason. Ferroelectr. Freq. Control. 2017; 64:164-176
- 254 2. Bercoff J, Tanter M, Fink M. Supersonic shear imaging: a new technique for soft tissue
255 elasticity mapping. IEEE transactions on ultrasonics, ferroelectrics, and frequency
256 control 2004; 51(4): 396–409.
- 257 3. Herman BA, Harris GR. Models and regulatory considerations for transient temperature
258 rise during diagnostic ultrasound pulses. Ultrasound Med. Biol. 2002; 28:1217-1224

- 259 4. Palmeri ML, Frinkley KD, Nightingale KR. Experimental studies of the thermal effects
260 associated with radiation force imaging of soft tissue. *Ultrason. Imaging* 2004; 26(2):100-
261 114
- 262 5. Food and Drug Administration. Information for manufacturers seeking marketing
263 clearance of diagnostic ultrasound systems and transducers. 2008; 1–64
- 264 6. Food and Drug Administration. Marketing clearance of diagnostic ultrasound systems
265 and transducers: Guidance for industry and food and drug administration staff. Food
266 Drug Admin., Silver Spring, MD, USA, Tech. Rep. FDA-2017-D-5372, 2019.
- 267 7. Duck AF. Safety standards and regulations: the manufacturers' responsibilities. In: Haar
268 G, editor. *The safe use of ultrasound in medical diagnosis* (3rd Ed.), London, United
269 Kingdom, The British Institute of Radiology 2012; 134–142
- 270 8. Miller DL, Abo A, Abramowicz JS, et al. Diagnostic ultrasound safety review for point-of-
271 care ultrasound practitioners. *J Ultrasound Med.* 2020; 39:1069-1084
- 272 9. Church CC, Labuda C, Nightingale K. A. Theoretical study of inertial cavitation from
273 acoustic radiation force impulse imaging and implications for the mechanical index.
274 *Ultrasound Med Biol.* 2015; 41:472-485
- 275 10. Bigelow TA, Church CC, Sandstrom K, et al. The thermal index: its strengths,
276 weaknesses, and proposed improvements. *J. Ultrasound Med.* 2011; 30: 714-734
- 277 11. Ziskin MC. The thermal dose index [published correction appears in *J. Ultrasound Med.*
278 2010; 29(12):1854]. *J. Ultrasound Med.* 2010; 29:1475-1479
- 279 12. Nightingale K. Acoustic radiation force impulse (ARFI) imaging: a review. *Curr Med*
280 *Imaging Rev.* 2011; 7:328-339

- 281 13. Yazdani L, Bhatt M, Rafati I, Tang A, Cloutier G. The revisited frequency-shift method
282 for shear wave attenuation computation and imaging. IEEE Transactions on
283 Ultrasonics, Ferroelectrics, and Frequency Control 2022; 69:2061-2074
- 284 14. Barry CT, Mills B, Hah Z et al. Shear wave dispersion measures liver steatosis.
285 Ultrasound in Medicine and Biology 2012; 38:175-182
- 286 15. Parker KJ, Partin A, Rubens DJ. What do we know about shear wave dispersion in
287 normal and steatotic livers? Ultrasound in Medicine and Biology 2015; 41:1481-1487

288 **Electronic Supplement Tables**

289 **Table S1**— Programmed parameters of the ultrasound sequence for human liver imaging.

Mode	Wave duration (μs)	Wave frequency (MHz)	Wave cycles	PRF (Hz)	Compounding (number of angles)	Focus depth (mm)	Frame rate (s⁻¹)	Wave amplitude (volts)
B-mode	0.64	3.125	2	1280	64	50	20	20
Diverging wave QUS	0.64	3.125	2	3145	21	NA	150	30
SWE push	357	2.778	992	2793	5	20-80	N/A	25 or 42
Diverging wave SWE tracking	0.64	3.125	2	6225	3	NA	2083	30

290 PRF: pulse repetition frequency, QUS: quantitative ultrasound, SWE: shear wave elastography.

291

292


293 **Table S2**— The voltage used for shear wave elastography (SWE) pushes at different user

294 selected push depths for human liver imaging.


Focus distance	20 mm	30 mm	40 mm	60 mm	80 mm
Voltage	25 V	25 V	42 V	42 V	42 V

295

296




299
 300 **Fig. S1**— Schematic of the human liver imaging sequence. ARF: acoustic radiation force, QUS:
 301 quantitative ultrasound, SWE: shear wave elastography.



302

303 **Fig. S2**— Measured mechanical index (MI) in shear wave elastography (SWE) mode as a
 304 function of the selected voltage for different focus depths using a hydrophone in a water tank.
 305 A derating attenuation value of $0.3 \text{ dB.MHz}^{-1}.\text{cm}^{-1}$ was considered for those measurements.
 306 The MIs and voltages in the blue box had never been used for human acquisitions.

307




309

310


311 **Fig. S3**— Measured intensity spatial peak temporal averaged (I_{SPTA}) in mW/cm^2 as a function
312 of the focus depth for the maximum selected voltage limit (**Table S2**) programmed on the
313 Verasonics system for human liver imaging.

314




315

316 **Fig. S4**— Estimated thermal index (TI) in °C as a function of the focus depth for the maximum
317 selected voltage limit (**Table S2**) programmed on the Verasonics system for human liver
318 imaging.



319

320 **Fig. S5**— Examples of shear wave attenuation and shear wave dispersion line fittings using A-
 321 RANSAC for one volunteer and one NAFLD patient (top and bottom rows represent line fitting
 322 of the rate parameter of the gamma distribution versus lateral distance for SWA computation,
 323 and line fitting of the phase velocity versus frequency for SWD computation, respectively). (a)
 324 30-years-old healthy volunteer woman (R^2 of the fitted line=0.97), (b) 62-years-old man with
 325 steatosis grade 2, lobular inflammation grade 2, ballooning grade 2, fibrosis stage 4 ($R^2=0.87$),
 326 (c) 32-year-old healthy volunteer man ($R^2=1$), and (d) 60-years-old woman with steatosis
 327 grade 3, lobular inflammation grade 3, ballooning grade 2, fibrosis stage 3 ($R^2=0.95$).



328

329 **Fig. S6**— The averaging procedure over the 10 acquisitions (SSI represents shear wave
 330 acquisitions with different angles of pushes lines).